Investigating the potential non‐authorized use of two different formulations of liraglutide in Europe: A real‐world drug utilization study
Sign Up to like & getrecommendations! Published in 2022 at "Diabetes"
DOI: 10.1111/dom.14945
Abstract: To assess the in‐market use of Saxenda (liraglutide 3.0 mg) and Victoza (liraglutide 1.2 mg/1.8 mg) according to approved indications and posology. read more here.
Keywords: investigating potential; non authorized; two different; potential non ... See more keywords